Resources

Presentations and videos

Minimal residual disease in Myeloma Session 1
Minimal residual disease in Myeloma Session 2
Improving Survival in Multiple Myeloma
What’s new in Myeloma Treatment: a New Zealand Perspective
CAR T-cell Therapy: a New Frontier in Blood Cancer Treatment
Four Decades of Myeloma – Ken Romeril

Research and articles

Frontline treatment of elderly non transplant-eligible multiple myeloma patients using CyBorD with or without thalidomide-based consolidation: a retrospective multi-centre analysis of real-world data

Bortezomib in combination with cyclophosphamide and dexamethasone (CyBorD, is a well-established frontline chemotherapy regimen for patients with multiple myeloma, but prospective data on elderly non-transplant eligible patients is limited. A...
Continue Reading

The VCAT study

Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study Development...
Continue Reading

Lenalidomide-related Progressive Multifocal Leukoencephalopathy: A Case Report and Review of Drug-related Cases in Multiple Myeloma

Progressive multifocal leukoencephalopathy (PML) is a rare demyelinating disease of the central nervous system caused by reactivation of John Cunningham (JC) virus. Risk factors for the development of PML include...
Continue Reading